Amikacin Once Daily Dosing is Preferred Over Twice Daily
For adult patients with normal renal function, amikacin should be administered once daily (15 mg/kg/day) rather than twice daily (7.5 mg/kg q12h). This recommendation is based on multiple high-quality guidelines and clinical evidence demonstrating equivalent or superior efficacy with comparable or reduced toxicity.
Dosing Recommendations by Clinical Context
Standard Dosing (Normal Renal Function)
- Once daily: 15 mg/kg/day (maximum 1.5 g/day) 1, 2, 3, 4
- Alternative twice daily: 7.5 mg/kg q12h 1, 4
- Alternative three times weekly: 15-25 mg/kg per dose 1, 2, 3
The FDA label explicitly states both regimens are acceptable, noting "15 mg/kg/day divided into 2 or 3 equal doses administered at equally-divided intervals, i.e., 7.5 mg/kg q12h or 5 mg/kg q8h" 4. However, once daily dosing leverages the concentration-dependent bactericidal activity of aminoglycosides, achieving higher peak concentrations that enhance bacterial killing.
Target Serum Concentrations
The monitoring targets differ significantly by regimen:
- Once daily dosing: Peak 25-35 mg/L (or 35-45 μg/mL), trough <5 mg/L 1, 5, 4
- Three times weekly dosing: Peak 65-80 mg/L 1, 5
- Twice daily dosing: Peak approximately 24 mg/L 6
Evidence Supporting Once Daily Dosing
Clinical Efficacy
Multiple randomized controlled trials demonstrate that once daily dosing is at least as effective as twice daily dosing, with some studies showing superior outcomes:
- A large Scandinavian multicenter trial (316 patients) showed 90% satisfactory clinical response with both regimens, with no significant differences in efficacy 6
- A critical care study (348 patients) demonstrated superior cure rates with once daily dosing: 83% vs 66% (P=0.001) for clinical cure and 81% vs 58% (P=0.005) for bacteriological cure 7
- An elderly patient study (39 patients) showed comparable efficacy and safety between regimens 8
Safety Profile
Once daily dosing appears to reduce nephrotoxicity risk:
- The critical care trial showed serum creatinine elevation in 21% with once daily vs 35% with twice daily dosing (P=0.05) 7
- The Scandinavian trial found no significant difference in nephrotoxic events (9 vs 11 events), with multivariate analysis showing low correlation between dosing frequency and nephrotoxicity 6
- Ototoxicity rates were similarly low in both groups across studies 6, 9
Pharmacokinetic Rationale
Population pharmacokinetic studies confirm that amikacin kinetics are linear across the dosing range of 7.5-20 mg/kg, with no influence of dosing regimen on pharmacokinetic parameters 10. The concentration-dependent killing and prolonged post-antibiotic effect of aminoglycosides support once daily administration.
Special Populations and Adjustments
Renal Impairment
Dosing frequency must be reduced, but the milligram dose should be maintained to preserve concentration-dependent bactericidal activity 2, 3, 2, 11:
- Creatinine clearance <30 mL/min or hemodialysis: 15 mg/kg per dose, 2-3 times per week 11
- Administer after dialysis to facilitate directly observed therapy and avoid premature drug removal 2, 3, 2
- Therapeutic drug monitoring is essential in renal impairment 2, 11
Elderly Patients (>59 years)
Reduce dose to 10 mg/kg/day (750 mg maximum) due to age-related decline in renal function 2, 3, 2
Obesity
Use ideal body weight plus 40% of excess weight for dose calculation 1:
- Male IBW (kg) = 50 + (2.3 × height in cm above 152.4)/2.54
- Female IBW (kg) = 45.5 + (2.3 × height in cm above 152.4)/2.54
Monitoring Requirements
Therapeutic Drug Monitoring
Essential when therapy extends beyond 48 hours 4:
- Peak levels: 90-120 minutes after infusion ends (or 60 minutes as alternative) 1
- Trough levels: Immediately before next dose 1
- Frequency: Peak in first week; trough weekly for 4 weeks, then fortnightly when stable 1
Toxicity Monitoring
Baseline assessments required 1, 2, 3, 2:
- Audiogram and vestibular testing
- Serum creatinine
- Romberg testing
During therapy:
- Renal function: Twice weekly (month 1), weekly (month 2), then fortnightly 1
- Monthly questioning about auditory/vestibular symptoms 2, 3, 2
- Repeat audiogram if symptoms develop
Critical Pitfalls to Avoid
Do not use smaller doses in renal impairment - this reduces efficacy. Instead, extend the dosing interval while maintaining the mg/kg dose 2, 3, 2, 11
Avoid peak concentrations >35 μg/mL and trough >10 μg/mL in standard dosing to minimize toxicity 4
Do not exceed 15 mg/kg/day total dose by any route 4
Limit treatment duration - reassess if therapy extends beyond 10 days, with intensified monitoring of drug levels and renal/auditory/vestibular function 4
Contraindicated in pregnancy due to fetal nephrotoxicity and congenital hearing loss risk 2, 3, 2
Context-Specific Considerations
Non-Tuberculous Mycobacterial Disease
For NTM pulmonary disease, both once daily and three times weekly regimens are used 1, 12, 5. Recent evidence suggests challenges in achieving guideline-recommended peak concentrations (65-80 mg/L for thrice weekly dosing), with most patients achieving only 47 μg/mL despite adequate dosing 13.
Tuberculosis
For drug-resistant TB, amikacin is typically initiated as 15 mg/kg once daily (5-7 days/week), then reduced to 2-3 times weekly after 2-4 months or culture conversion 2, 3, 2